Piramal Pharma Solutions and NewAmsterdam Pharma Announce Strategic Investment to Expand Solid Oral Dosage Manufacturing Capabilities in Sellersville, Pennsylvania
Sellersville, Pennsylvania – August 24, 2025 – Piramal Pharma Solutions (PPS), a leading global integrated contract development and manufacturing organization (CDMO), and NewAmsterdam Pharma (NAP), a clinical-stage biopharmaceutical company, have jointly announced a significant investment to establish a specialized manufacturing area at Piramal Pharma Solutions’ Sellersville, Pennsylvania facility. This strategic expansion is set to enhance the production capabilities for solid oral dosage forms, underscoring a commitment to bolstering critical pharmaceutical manufacturing infrastructure in the United States.
The collaboration between PPS and NAP signifies a mutual dedication to advancing pharmaceutical production and ensuring the reliable supply of vital medications. This investment will focus on creating a state-of-the-art manufacturing space dedicated to solid oral dosage forms, a prevalent and essential category of pharmaceutical products. The expanded capabilities will allow for greater flexibility and capacity to meet the growing demands of the pharmaceutical market.
The Sellersville site, already a well-established hub for pharmaceutical manufacturing, will benefit from this strategic enhancement. The new specialized area is designed to incorporate advanced technologies and adhere to the highest quality and regulatory standards, ensuring the efficient and compliant production of a wide range of solid oral dosage formulations.
This initiative is particularly noteworthy for its potential to strengthen domestic pharmaceutical manufacturing capacity. By investing in US-based production, both Piramal Pharma Solutions and NewAmsterdam Pharma are contributing to a more resilient and responsive pharmaceutical supply chain, which is crucial for patient access to medicines.
“We are delighted to partner with NewAmsterdam Pharma on this important initiative,” said [Insert Name and Title of PPS Spokesperson, if available]. “This investment in our Sellersville facility reflects our ongoing commitment to providing world-class manufacturing services to our clients and to supporting the growth of critical pharmaceutical production within the United States. The expansion of our solid oral dosage manufacturing capabilities will enable us to serve our partners with even greater efficiency and expertise.”
[Insert Name and Title of NAP Spokesperson, if available], from NewAmsterdam Pharma, added, “This collaboration with Piramal Pharma Solutions represents a significant step forward in our mission to bring innovative therapies to patients. By investing in these expanded manufacturing capabilities, we are ensuring that our pipeline products, and potentially other important medications, can be produced with the highest quality and reliability. We are confident that the Sellersville site, with its established expertise and this new specialized area, will be instrumental in our success.”
The expansion is expected to create new opportunities and further solidify the Sellersville site’s position as a key player in pharmaceutical manufacturing. Both companies express their enthusiasm for the project and the positive impact it will have on the broader pharmaceutical landscape.
AI has delivered the news.
The answer to the following question is obtained from Google Gemini.
www.prnewswire.com published ‘Piramal Pharma Solutions und NewAmsterdam Pharma investieren in einen spezialisierten Produktionsbereich, um die Herstellungskapazitäten fester oraler Darreichungsformen am Piramal-Standort in Sellersville, Pennsylvania, zu erweitern’ at 2025-08-24 14:04. Please write a detailed article about this news in a polite tone with relevant information. Please reply in English with the article only.